Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Randomized, Double-blind, Placebo-controlled, First-In-Human, Phase I Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 Following Administration of Single and Multiple Ascending Oral Doses in Healthy Volunteers

NCT03796910 is registered in ClinicalTrials.gov with Spero Therapeutics as lead sponsor.

NCT NCT03796910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03796910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Randomized, Double-blind, Placebo-controlled, First-In-Human, Phase I Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 Following Administration of Single and Multiple Ascending Oral Doses in Healthy Volunteers
Lead sponsor
Spero Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 18, 2018
Completion date
September 24, 2019
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers